MLchartDataset catalogue

Riabni

Term · Oncology and biomedicine · MLC-T-ONC-007437

A drug that contains the active ingredient rituximab and is used alone or with other drugs to treat adults with certain types of B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that are CD20 positive. It is also being studied in the treatment of other conditions and types of cancer. Riabni binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Riabni is a type of monoclonal antibody.

Table 1. Record
IdentifierMLC-T-ONC-007437
FieldOncology and biomedicine
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-007437",
  "term": "Riabni",
  "field": "Oncology and biomedicine",
  "definition": "A drug that contains the active ingredient rituximab and is used alone or with other drugs to treat adults with certain types of B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that are CD20 positive. It is also being studied in the treatment of other conditions and types of cancer. Riabni binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Riabni is a type of monoclonal antibody.",
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/riabni/"
}

Record 14,455 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.